首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL36G |
| Uniprot No | Q9NZH8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-169aa |
| 氨基酸序列 | MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND |
| 预测分子量 | 18.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL36G重组蛋白的3篇参考文献的简要信息整理：
---
1. **文献名称**：*Recombinant IL-36γ promotes keratinocyte inflammation and enhances psoriatic epidermal hyperplasia*
**作者**：Carrier Y et al.
**摘要**：该研究通过在大鼠模型中表达重组IL-36γ蛋白，发现其能显著诱导皮肤角质细胞炎症反应，并加剧银屑病样表皮增生，提示IL-36γ在银屑病发病机制中的关键作用。
---
2. **文献名称**：*Structural and functional characterization of recombinant human IL-36γ: A pro-inflammatory cytokine in the IL-1 family*
**作者**：Boraschi D et al.
**摘要**：文章报道了人源重组IL-36γ蛋白的高效表达与纯化，并通过晶体结构解析和体外实验，揭示其通过激活NF-κB信号通路驱动促炎因子(如IL-6、IL-8)释放的分子机制。
---
3. **文献名称**：*IL-36γ reprograms colonic epithelial cells to promote chronic intestinal inflammation*
**作者**：Scheibe K et al.
**摘要**：研究利用重组IL-36γ蛋白处理结肠上皮细胞，证明其通过上调趋化因子表达招募免疫细胞浸润，促进肠道慢性炎症反应，为炎症性肠病的治疗提供潜在靶点。
---
(注：以上文献信息为示例性内容，实际文献需通过数据库检索获取。)
Interleukin-36 gamma (IL-36γ), encoded by the IL36G gene, is a pro-inflammatory cytokine belonging to the IL-1 superfamily. It plays a critical role in modulating immune responses, particularly in skin and mucosal tissues. IL-36γ is primarily expressed by epithelial cells, keratinocytes, and immune cells, where it activates signaling pathways through the IL-36 receptor (IL-36R) complex, triggering downstream NF-κB and MAPK cascades. This cytokine is implicated in amplifying inflammatory reactions, recruiting immune cells, and maintaining tissue homeostasis. Dysregulation of IL-36γ has been linked to chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease, making it a potential therapeutic target or biomarker.
Recombinant IL-36γ protein is engineered using biotechnological methods, often expressed in Escherichia coli or mammalian cell systems to ensure proper folding and post-translational modifications. The purified protein retains biological activity, enabling researchers to study its interactions, signaling mechanisms, and pathological roles in vitro or in animal models. Its applications span drug discovery (e.g., testing IL-36R antagonists), mechanistic studies of autoimmune disorders, and vaccine adjuvant development due to its immune-potentiating properties. However, challenges remain in optimizing stability, minimizing off-target effects, and understanding context-specific functions across different tissues. As research progresses, recombinant IL-36γ continues to serve as a vital tool for unraveling immune regulation and advancing targeted anti-inflammatory therapies.
×
